iBio Announces Co. Has Signed A Definitive Worldwide Exclusive License Agreement With RubrYc Therapeutics For RTX-003, An Immunotherapy Candidate Targeting Regulatory T Cells; iBio Made An Upfront $5M Payment To RubrYc, With An Additional $2.5M Commitment For December 2021